Satish Babu Moparthi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Satish Babu Moparthi has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Stéphane Vassilopoulos
Sorbonne Université, INSERM, Institute of Myology, Centre of Research in Myology, UMRS 974, Paris, France
7 shared publications - Adai Colom
Biofisika Institute (CSIC, UPV/EHU) and Department of Biochemistry and Molecular Biology, University of the Basque Country, Leioa, Spain
2 shared publications - Aurélien Roux
Department of Biochemistry, University of Geneva, Geneva, Switzerland.
2 shared publications - Carlos Marcuello
Biofisika Institute (CSIC, UPV/EHU) and Department of Biochemistry and Molecular Biology, University of the Basque Country, Leioa, Spain
2 shared publications - Javier Espadas
Department of Biochemistry, University of Geneva, Geneva, Switzerland
2 shared publications Jeanne Lainé
Sorbonne Université, INSERM, Institute of Myology, Centre of Research in Myology, UMRS 974, Paris, France
2 shared publications
Latest Publications
- Open Access
Piezo1 balances focal and reticular adhesions to enable EGFR clathrin-mediated endocytosis
Cells attach to the extracellular matrix through distinct integrin-mediated adhesive structures, including force-transmitting focal adhesions (FAs) and clathrin-enriched reticular adhesions (RAs). FAs enable mesenchymal cell migration and disassemble at mitotic entry, whereas RAs impede migration, persist during mitosis, and contribute to clathrin-mediated endocytosis (CME) as they disassemble. FAs grow with RhoA contractility, whereas RAs shrink, but the mechanisms coordinating these opposing responses remain unclear. Here, we identify the mechanically activated ion channel Piezo1 as a master regulator of FA/RA balance. Piezo1-dependent calcium influx activates the Src family kinase Fyn, which activates two actin polymerization pathways: FA and stress fiber growth via VAV2-RhoA and RA disassembly via N-WASP-Arp2/3. Inhibition or knockdown of Piezo1, Fyn, or VAV2 decreases FA size and increases RA coverage. Critically, cells lacking Piezo1 fail to internalize ligand-activated EGFR on stiff substrates despite normal CME on soft substrates, establishing an essential role for Piezo1 in EGFR CME mechanoadaption. Our findings reveal Piezo1 as the mechanosensor linking membrane tension to coordinated actin polymerization pathways that co-regulate cell-matrix adhesion and endocytosis. Given that CME contributes to viral entry into host cells and cancer resistance to anti-EGFR antibody therapy, targeting the Piezo1-RA-CME axis may offer novel therapeutic opportunities.
Open AccessPiezo1 balances focal and reticular adhesions to enable EGFR clathrin-mediated endocytosis
Cells attach to the extracellular matrix through distinct integrin-mediated adhesive structures, including force-transmitting focal adhesions (FAs) and clathrin-enriched reticular adhesions (RAs). FAs enable mesenchymal cell migration and disassemble at mitotic entry, whereas RAs impede migration, persist during mitosis, and contribute to clathrin-mediated endocytosis (CME) as they disassemble. FAs grow with RhoA contractility, whereas RAs shrink, but the mechanisms coordinating these opposing responses remain unclear. Here, we identify the mechanically activated ion channel Piezo1 as a master regulator of FA/RA balance. Piezo1-dependent calcium influx activates the Src family kinase Fyn, which activates two actin polymerization pathways: FA and stress fiber growth via VAV2-RhoA and RA disassembly via N-WASP-Arp2/3. Inhibition or knockdown of Piezo1, Fyn, or VAV2 decreases FA size and increases RA coverage. Critically, cells lacking Piezo1 fail to internalize ligand-activated EGFR on stiff substrates despite normal CME on soft substrates, establishing an essential role for Piezo1 in EGFR CME mechanoadaption. Our findings reveal Piezo1 as the mechanosensor linking membrane tension to coordinated actin polymerization pathways that co-regulate cell-matrix adhesion and endocytosis. Given that CME contributes to viral entry into host cells and cancer resistance to anti-EGFR antibody therapy, targeting the Piezo1-RA-CME axis may offer novel therapeutic opportunities.
- Open Access
- 31 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (31)
Genetic screening identifies WNT5A/RYK as a determinant of extracellular vesicle fate
Extracellular vesicles (EVs) are natural mediators of intercellular communication through the transfer of cytoplasmic material from donor to recipient cells. The molecular mechanisms governing EV uptake and cargo delivery in recipient cells remain largely elusive. To address this gap, we performed a genetic screening interrogating 300 genes of the dynamic surfaceome for their involvement in EV uptake. Activators found in the screening establish a previously unknown connection between EV uptake and Wnt pathways. We then observed that, unlike WNT-naïve EVs that are primarily trafficked to lysosomes in recipient cells, WNT5A-bearing EVs linger in early endocytic structures. This rerouting is dependent on the expression of RYK, an established co-receptor for WNT5A. Our results depict a mechanism underlying EV functional heterogeneity as well as reveal a potential regulation system for noncanonical WNT signaling.
- 31 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (31)
Open AccessGenetic screening identifies WNT5A/RYK as a determinant of extracellular vesicle fate
Extracellular vesicles (EVs) are natural mediators of intercellular communication through the transfer of cytoplasmic material from donor to recipient cells. The molecular mechanisms governing EV uptake and cargo delivery in recipient cells remain largely elusive. To address this gap, we performed a genetic screening interrogating 300 genes of the dynamic surfaceome for their involvement in EV uptake. Activators found in the screening establish a previously unknown connection between EV uptake and Wnt pathways. We then observed that, unlike WNT-naïve EVs that are primarily trafficked to lysosomes in recipient cells, WNT5A-bearing EVs linger in early endocytic structures. This rerouting is dependent on the expression of RYK, an established co-receptor for WNT5A. Our results depict a mechanism underlying EV functional heterogeneity as well as reveal a potential regulation system for noncanonical WNT signaling.
- Open Access
- 12 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Two-dimensional HRS condensates drive the assembly of flat clathrin lattices on endosomes
In cells, the curved clathrin structures in vesicle budding are well characterized, while the flat ones remain poorly understood. Here, we reconstitute the flat assembly of ESCRT-0 protein HRS and clathrin onto lipid membranes in vitro. HRS forms gel-like protein condensates at micromolar concentrations in solutions. These condensates spread as a two-dimensional layer on negatively charged membranes and, together with clathrin, form multilayered coats. Importantly, the two-dimensional condensates spontaneously form only on membranes at HRS concentrations below 50 nM, its cytoplasmic concentration. Correlative cryo-electron tomography of HRS-labelled endosomes in cells reveals a multilayered structure containing a flat clathrin layer 16 nm away from the membrane, consistent with our in vitro findings. Cholesterol enhances HRS recruitment to the membrane both in cells and in supported bilayers. Furthermore, cholesterol promotes the phase separation of HRS onto membranes, which in turn concentrates cholesterol underneath. This positive feedback promotes the formation of HRS-clathrin microdomains that sorts reconstituted ubiquitinated cargoes. Altogether, our results show that the distinct architecture of ESCRT-0 is assembled by the two-dimensional phase-separation of HRS which drives the assembly of flat clathrin coats.
- 12 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTwo-dimensional HRS condensates drive the assembly of flat clathrin lattices on endosomes
In cells, the curved clathrin structures in vesicle budding are well characterized, while the flat ones remain poorly understood. Here, we reconstitute the flat assembly of ESCRT-0 protein HRS and clathrin onto lipid membranes in vitro. HRS forms gel-like protein condensates at micromolar concentrations in solutions. These condensates spread as a two-dimensional layer on negatively charged membranes and, together with clathrin, form multilayered coats. Importantly, the two-dimensional condensates spontaneously form only on membranes at HRS concentrations below 50 nM, its cytoplasmic concentration. Correlative cryo-electron tomography of HRS-labelled endosomes in cells reveals a multilayered structure containing a flat clathrin layer 16 nm away from the membrane, consistent with our in vitro findings. Cholesterol enhances HRS recruitment to the membrane both in cells and in supported bilayers. Furthermore, cholesterol promotes the phase separation of HRS onto membranes, which in turn concentrates cholesterol underneath. This positive feedback promotes the formation of HRS-clathrin microdomains that sorts reconstituted ubiquitinated cargoes. Altogether, our results show that the distinct architecture of ESCRT-0 is assembled by the two-dimensional phase-separation of HRS which drives the assembly of flat clathrin coats.
- Open Access
- 1 January 2025
- Published by ScienceOpen in Drug Repurposing
- Vol. 2 (2) , 20250006
DREAMS: Drug REpurposing with Artificial Intelligence for Muscular Disorders
Rare diseases affect over 300 million people worldwide, yet only 6% currently have an approved treatment option. Given these numbers, and the pharmaceutical industry’s traditional “one drug, one disease” paradigm, it is crucial to develop disruptive approaches that accelerate drug discovery while reducing development time and costs. To address this challenge, the DREAMS project aims to identify repurposable treatments for multiple rare diseases by targeting shared pathological phenotypes. Our approach is built on four key pillars: (i) disease modeling using patient-derived pluripotent stem cells to identify common pathological phenotypes; (ii) phenotypic screening to identify compounds that rescue these molecular and cellular dysfunctions; (iii) artificial intelligence-based target deconvolution to understand mechanisms of action, predict therapeutic targets, and propose new disease indications; and (iv) innovative clinical trial methodologies designed to address groups of diseases rather than single conditions. Importantly, DREAMS is deeply patient-centric, with patient representatives actively involved in the design of the clinical trial to ensure that the research aligns with patients’ needs and priorities. To develop this approach, DREAMS specifically focuses on rare neuromuscular disorders that share a key pathological mechanism: impaired autophagy in striated muscle tissue. Five genetic diseases were selected based on their clinical relevance and preclinical evidence demonstrating that autophagy rescue can be beneficial: dynamin 2-related centronuclear myopathy, Duchenne muscular dystrophy, LMNA-related Emery–Dreifuss muscular dystrophy type 2, glycogen storage disease type II (Pompe disease), and Danon disease. By focusing on shared mechanisms rather than disease-specific mutations, DREAMS establishes a scalable and reusable platform for drug discovery that can be applied to additional rare diseases with overlapping pathophysiological features.
- 1 January 2025
- Published by ScienceOpen in Drug Repurposing
- Vol. 2 (2) , 20250006
Open AccessDREAMS: Drug REpurposing with Artificial Intelligence for Muscular Disorders
Rare diseases affect over 300 million people worldwide, yet only 6% currently have an approved treatment option. Given these numbers, and the pharmaceutical industry’s traditional “one drug, one disease” paradigm, it is crucial to develop disruptive approaches that accelerate drug discovery while reducing development time and costs. To address this challenge, the DREAMS project aims to identify repurposable treatments for multiple rare diseases by targeting shared pathological phenotypes. Our approach is built on four key pillars: (i) disease modeling using patient-derived pluripotent stem cells to identify common pathological phenotypes; (ii) phenotypic screening to identify compounds that rescue these molecular and cellular dysfunctions; (iii) artificial intelligence-based target deconvolution to understand mechanisms of action, predict therapeutic targets, and propose new disease indications; and (iv) innovative clinical trial methodologies designed to address groups of diseases rather than single conditions. Importantly, DREAMS is deeply patient-centric, with patient representatives actively involved in the design of the clinical trial to ensure that the research aligns with patients’ needs and priorities. To develop this approach, DREAMS specifically focuses on rare neuromuscular disorders that share a key pathological mechanism: impaired autophagy in striated muscle tissue. Five genetic diseases were selected based on their clinical relevance and preclinical evidence demonstrating that autophagy rescue can be beneficial: dynamin 2-related centronuclear myopathy, Duchenne muscular dystrophy, LMNA-related Emery–Dreifuss muscular dystrophy type 2, glycogen storage disease type II (Pompe disease), and Danon disease. By focusing on shared mechanisms rather than disease-specific mutations, DREAMS establishes a scalable and reusable platform for drug discovery that can be applied to additional rare diseases with overlapping pathophysiological features.
- Open Access
Two-dimensional HRS condensates drive the assembly of flat clathrin lattices on endosomes
In cells, the curved clathrin structures in vesicle budding are well characterized, while the flat ones remain poorly understood. We reconstituted the flat assembly of ESCRT-0 protein HRS and clathrin onto lipid membranes in vitro . HRS was found to form protein condensates. These condensates spread as a two-dimensional layer on negatively charged membranes and promoted the assembly of clathrin into a flat coat. Correlative cryo-tomography of HRS-labeled endosomes revealed a pure hexagonal lattice, consistent with flat clathrin structures. Cholesterol enhanced HRS recruitment to the membrane both in cells and in supported bilayers. Furthermore, cholesterol promoted the phase separation of HRS onto membranes, which in turn concentrated cholesterol underneath. This positive feedback promoted the formation of HRS-clathrin microdomains that sorted reconstituted ubiquitinated cargoes. Altogether, our results show that the unique architecture of ESCRT-0 is assembled by the two-dimensional phase-separation of HRS which drives the assembly of flat clathrin coats.
Open AccessTwo-dimensional HRS condensates drive the assembly of flat clathrin lattices on endosomes
In cells, the curved clathrin structures in vesicle budding are well characterized, while the flat ones remain poorly understood. We reconstituted the flat assembly of ESCRT-0 protein HRS and clathrin onto lipid membranes in vitro . HRS was found to form protein condensates. These condensates spread as a two-dimensional layer on negatively charged membranes and promoted the assembly of clathrin into a flat coat. Correlative cryo-tomography of HRS-labeled endosomes revealed a pure hexagonal lattice, consistent with flat clathrin structures. Cholesterol enhanced HRS recruitment to the membrane both in cells and in supported bilayers. Furthermore, cholesterol promoted the phase separation of HRS onto membranes, which in turn concentrated cholesterol underneath. This positive feedback promoted the formation of HRS-clathrin microdomains that sorted reconstituted ubiquitinated cargoes. Altogether, our results show that the unique architecture of ESCRT-0 is assembled by the two-dimensional phase-separation of HRS which drives the assembly of flat clathrin coats.
- 4 June 2024
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 31 (9) , 1448-1459
ATG16L1 induces the formation of phagophore-like membrane cups
The hallmark of non-selective autophagy is the formation of cup-shaped phagophores that capture bulk cytoplasm. The process is accompanied by the conjugation of LC3B to phagophores by an E3 ligase complex comprising ATG12–ATG5 and ATG16L1. Here we combined two complementary reconstitution approaches to reveal the function of LC3B and its ligase complex during phagophore expansion. We found that LC3B forms together with ATG12–ATG5–ATG16L1 a membrane coat that remodels flat membranes into cups that closely resemble phagophores. Mechanistically, we revealed that cup formation strictly depends on a close collaboration between LC3B and ATG16L1. Moreover, only LC3B, but no other member of the ATG8 protein family, promotes cup formation. ATG16L1 truncates that lacked the C-terminal membrane binding domain catalyzed LC3B lipidation but failed to assemble coats, did not promote cup formation and inhibited the biogenesis of non-selective autophagosomes. Our results thus demonstrate that ATG16L1 and LC3B induce and stabilize the characteristic cup-like shape of phagophores.
- 4 June 2024
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 31 (9) , 1448-1459
ATG16L1 induces the formation of phagophore-like membrane cups
The hallmark of non-selective autophagy is the formation of cup-shaped phagophores that capture bulk cytoplasm. The process is accompanied by the conjugation of LC3B to phagophores by an E3 ligase complex comprising ATG12–ATG5 and ATG16L1. Here we combined two complementary reconstitution approaches to reveal the function of LC3B and its ligase complex during phagophore expansion. We found that LC3B forms together with ATG12–ATG5–ATG16L1 a membrane coat that remodels flat membranes into cups that closely resemble phagophores. Mechanistically, we revealed that cup formation strictly depends on a close collaboration between LC3B and ATG16L1. Moreover, only LC3B, but no other member of the ATG8 protein family, promotes cup formation. ATG16L1 truncates that lacked the C-terminal membrane binding domain catalyzed LC3B lipidation but failed to assemble coats, did not promote cup formation and inhibited the biogenesis of non-selective autophagosomes. Our results thus demonstrate that ATG16L1 and LC3B induce and stabilize the characteristic cup-like shape of phagophores.
- Open Access
The actin-spectrin submembrane scaffold restricts endocytosis along proximal axons
Neuronal clathrin-mediated endocytosis has unique features in compartments such as dendrites and presynaptic boutons, but how membrane and extracellular components are internalized along the axon shaft remains poorly known. Here we focused on clathrin-coated structures and endocytosis along the axon initial segment (AIS), and their relationship to the periodic actin-spectrin scaffold that lines the axonal plasma membrane. Super-resolution optical microscopy, platinum replica electron microscopy, and their correlative combination on cultured hippocampal neurons reveal that in the AIS, clathrin-coated pits form on bare membrane patches, ∼300 nm circular areas devoid of spectrin mesh and lined by actin filaments we termed “clearings”. In fibroblasts and the proximal axon of neurons, spectrin depletion and drug-induced scaffold disorganization increase clathrin-coated pit formation. However, the presence of clathrin-coated pits at the AIS is not directly linked to actual endocytosis: using cargo uptake and live-cell imaging experiments, we find that most AIS clathrin-coated pits are long-lived and immobile within the spectrin mesh clearings. Direct perturbation of the spectrin scaffold as well as elevated neuronal activity could induce endocytosis downstream of clathrin pit formation, showing that spectrin clearings are structures responsible for regulated endocytosis at the AIS.
Open AccessThe actin-spectrin submembrane scaffold restricts endocytosis along proximal axons
Neuronal clathrin-mediated endocytosis has unique features in compartments such as dendrites and presynaptic boutons, but how membrane and extracellular components are internalized along the axon shaft remains poorly known. Here we focused on clathrin-coated structures and endocytosis along the axon initial segment (AIS), and their relationship to the periodic actin-spectrin scaffold that lines the axonal plasma membrane. Super-resolution optical microscopy, platinum replica electron microscopy, and their correlative combination on cultured hippocampal neurons reveal that in the AIS, clathrin-coated pits form on bare membrane patches, ∼300 nm circular areas devoid of spectrin mesh and lined by actin filaments we termed “clearings”. In fibroblasts and the proximal axon of neurons, spectrin depletion and drug-induced scaffold disorganization increase clathrin-coated pit formation. However, the presence of clathrin-coated pits at the AIS is not directly linked to actual endocytosis: using cargo uptake and live-cell imaging experiments, we find that most AIS clathrin-coated pits are long-lived and immobile within the spectrin mesh clearings. Direct perturbation of the spectrin scaffold as well as elevated neuronal activity could induce endocytosis downstream of clathrin pit formation, showing that spectrin clearings are structures responsible for regulated endocytosis at the AIS.
- 25 January 2010
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 49 (6) , 1137-1145
Chaperone Activity of Cyp18 through Hydrophobic Condensation That Enables Rescue of Transient Misfolded Molten Globule Intermediates
The single-domain cyclophilin 18 (Cyp18) has long been known to function as a peptidyl-prolyl cis/trans isomerase (PPI) and was proposed by us to also function as a chaperone [Freskgard, P.-O., Bergenhem, N., Jonsson, B.-H., Svensson, M., and Carlsson, U. (1992) Science 258, 466-468]. Later several multidomain PPIs were demonstrated to work as both a peptidyl-prolyl cis/trans isomerase and a chaperone. However, the chaperone ability of Cyp18 has been debated. In this work, we add additional results that show that Cyp18 can both accelerate the rate of refolding and increase the yield of native protein during the folding reaction, i.e., function as both a folding catalyst and a chaperone. Refolding experiments were performed using severely destabilized mutants of human carbonic anhydrase II under conditions where the unfolding reaction is significant and a larger fraction of a more destabilized variant populates molten globule-like intermediates during refolding. A correlation of native state protein stability of the substrate protein versus Cyp18 chaperone activity was demonstrated. The induced correction of misfolded conformations by Cyp18 likely functions through rescue from misfolding of transient molten globule intermediates. ANS binding data suggest that the interaction by Cyp18 leads to an early stage condensation of accessible hydrophobic portions of the misfolding-prone protein substrate during folding. The opposite effect was observed for GroEL known as an unfoldase at early stages of refolding. The chaperone effect of Cyp18 was also demonstrated for citrate synthase, suggesting a general chaperone effect of this PPI.
- 25 January 2010
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 49 (6) , 1137-1145
Chaperone Activity of Cyp18 through Hydrophobic Condensation That Enables Rescue of Transient Misfolded Molten Globule Intermediates
The single-domain cyclophilin 18 (Cyp18) has long been known to function as a peptidyl-prolyl cis/trans isomerase (PPI) and was proposed by us to also function as a chaperone [Freskgard, P.-O., Bergenhem, N., Jonsson, B.-H., Svensson, M., and Carlsson, U. (1992) Science 258, 466-468]. Later several multidomain PPIs were demonstrated to work as both a peptidyl-prolyl cis/trans isomerase and a chaperone. However, the chaperone ability of Cyp18 has been debated. In this work, we add additional results that show that Cyp18 can both accelerate the rate of refolding and increase the yield of native protein during the folding reaction, i.e., function as both a folding catalyst and a chaperone. Refolding experiments were performed using severely destabilized mutants of human carbonic anhydrase II under conditions where the unfolding reaction is significant and a larger fraction of a more destabilized variant populates molten globule-like intermediates during refolding. A correlation of native state protein stability of the substrate protein versus Cyp18 chaperone activity was demonstrated. The induced correction of misfolded conformations by Cyp18 likely functions through rescue from misfolding of transient molten globule intermediates. ANS binding data suggest that the interaction by Cyp18 leads to an early stage condensation of accessible hydrophobic portions of the misfolding-prone protein substrate during folding. The opposite effect was observed for GroEL known as an unfoldase at early stages of refolding. The chaperone effect of Cyp18 was also demonstrated for citrate synthase, suggesting a general chaperone effect of this PPI.
- 14 July 2009
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 24 (11) , 1303-1310
pRb2/p130 protein in relation to clinicopathological and biological variables in rectal cancers with a clinical trial of preoperative radiotherapy
PRb2/p130 plays a key role in cell proliferation and is a considerable progress about expression patterns of pRb2/p130 in number of malignancies. However, pRb2/p130 expression and its significance in rectal cancer remain unknown. The purpose of the present study was to investigate pRb2/p130 protein patterns and their correlations with clinicopathological and biological factors in rectal cancer patients with or without preoperative radiotherapy (RT). pRb2/p130 protein was examined by immunohistochemistry in 130 primary tumors, along with the corresponding 61 distant normal mucosa specimens, 85 adjacent normal mucosa specimens, 34 lymph node metastases, and 93 primary tumor biopsies from rectal cancer patients who participated in a Swedish clinical trial of preoperative RT. The pRb2/p130 protein was mainly localized in the cytoplasm of tumor cells. In nonradiated cases, the lack of pRb2/p130 was related to advanced tumor–node–metastases stage, poorer differentiation, weak fibrosis, less inflammatory infiltration, higher Ki-67, and positive Cox-2 expression (p < 0.05). In radiated cases, the lack of pRb2/p130 was related to nonstaining of Cox-2 and survivin (p < 0.05). pRb2/p130 protein in primary tumors tended to be increased after RT (27% vs 16%, p = 0.07). pRb2/p130 was mainly localized in the cytoplasm rather than in the nucleus in rectal cancer. After RT, pRb2/p130 protein seems to be increased in primary tumors, and further the relationship of the pRb2/p130 with the clinicopathological and biological variables changed compared to the nonradiated cases. However, we did not find that the pRb2/p130 was directly related to RT, tumor recurrence, and patients' survival.
- 14 July 2009
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 24 (11) , 1303-1310
pRb2/p130 protein in relation to clinicopathological and biological variables in rectal cancers with a clinical trial of preoperative radiotherapy
PRb2/p130 plays a key role in cell proliferation and is a considerable progress about expression patterns of pRb2/p130 in number of malignancies. However, pRb2/p130 expression and its significance in rectal cancer remain unknown. The purpose of the present study was to investigate pRb2/p130 protein patterns and their correlations with clinicopathological and biological factors in rectal cancer patients with or without preoperative radiotherapy (RT). pRb2/p130 protein was examined by immunohistochemistry in 130 primary tumors, along with the corresponding 61 distant normal mucosa specimens, 85 adjacent normal mucosa specimens, 34 lymph node metastases, and 93 primary tumor biopsies from rectal cancer patients who participated in a Swedish clinical trial of preoperative RT. The pRb2/p130 protein was mainly localized in the cytoplasm of tumor cells. In nonradiated cases, the lack of pRb2/p130 was related to advanced tumor–node–metastases stage, poorer differentiation, weak fibrosis, less inflammatory infiltration, higher Ki-67, and positive Cox-2 expression (p < 0.05). In radiated cases, the lack of pRb2/p130 was related to nonstaining of Cox-2 and survivin (p < 0.05). pRb2/p130 protein in primary tumors tended to be increased after RT (27% vs 16%, p = 0.07). pRb2/p130 was mainly localized in the cytoplasm rather than in the nucleus in rectal cancer. After RT, pRb2/p130 protein seems to be increased in primary tumors, and further the relationship of the pRb2/p130 with the clinicopathological and biological variables changed compared to the nonradiated cases. However, we did not find that the pRb2/p130 was directly related to RT, tumor recurrence, and patients' survival.